Moolec Science S.A. (MLEC) is a Biotechnology company in the Healthcare sector, currently trading at $7.41. It has a SharesGrow Score of 32/100, indicating a weak investment profile with 1 out of 7 criteria passed.
Analyst consensus target is MLEC = $3 (-59.5% upside).
Valuation: MLEC trades at a trailing Price-to-Earnings (P/E) of -0 (S&P 500 average ~25).
Financials: revenue is $334M, +3176.1%/yr average growth. Net income is $111M (loss), growing at -794.1%/yr. Net profit margin is -33.4% (negative). Gross margin is 34.2% (+50 pp trend).
Balance sheet: total debt is $247M with negative equity of -$66M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 0.13 (tight liquidity). Debt-to-assets is 120.6%. Total assets: $205M.
Analyst outlook: 1 / 1 analysts rate MLEC as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 50/100 (Partial), Growth 58/100 (Partial), Past 0/100 (Fail), Health 0/100 (Fail), Moat 44/100 (Fail), Future 64/100 (Pass), Income 10/100 (Fail).
